Global Kinetics Corporation is the maker of the Personal KinetiGraph, a wearable that tracks movement in Parkinson’s patients. The device remind patients when to take their medications and even helps their doctors make an accurate diagnosis. The FDA-approved device is worn by 14,500 patients in more than 200 clinics around the world. It is intended to be worn for seven days, so physicians can identify important changes and trends. Global Kinetics in 2016 announced a randomized, controlled trial in partnership with the National Parkinson Foundation to study the impact of the device in 400 patients and determine how technology can be used in future clinical care. Going forward, Global Kinetics says its technology can be expanded to other diseases, including Huntington's disease, Alzheimer's disease, and epilepsy. The company makes money by partnering with pharmaceutical companies to use the technology in clinical trials for medicines being developed for Parkinson’s, but it also developing a business model based on direct-to-consumer sales.
public or private: Private
headquarters: Melbourne, Australia